Nasal Drug Delivery Market

Nasal Drug Delivery Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Target Indication (Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome), Type of Molecule (Biologics and Small Molecule), Type of Drug (TrudhesaTM, Tyrvaya, VALTACO®, SPRAVATO®, BAQSIMITM, NAYZILAM®, Tosyma®, XHANCETM, SINUVA, NeffyTM, ZAVEGEPANT (BHV-3500), LV-101, MEDI3250, and DEXANEUROSONE™) and Key Geographical Regions (North America, Europe and Asia Pacific, Latin America, Middle East, and North Africa)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    112

  • Pages
    252

  • View Count
    11214

-At present, 19 start-ups are driving innovation in this domain; various R&D initiatives have been undertaken by these players over the last few years

Nasal Drug Delivery Market Size & Share

The global nasal drug delivery market size was estimated to grow from USD 3.6 billion in 2023 to USD 26.8 billion by 2035, growing at a CAGR of 18.3% during the forecast period. 

Over the past few years, the prevalence of neurological disorders has increased at an annualized rate of 10.9%. Further, the mortality associated with such diseases is projected to account for 12.2% of the global death rate, in 2030. In this context, several research initiatives are underway to identify an approach that allows effective delivery of the target medication directly into the brain. One key challenge currently faced by researchers is the presence of the complex blood brain barrier (BBB), which hinders the entry of the target drug into the CNS, acting as a significant roadblock in the development of effective treatment modalities.

It is worth mentioning that the failure of the ongoing research initiatives can incur losses worth USD 2 billion. As a result, stakeholders in the pharmaceutical domain have shifted their focus towards the use of intranasal treatments, which have demonstrated to be capable of bypassing the blood brain barrier, thereby, delivering the target drug directly into the brain. Clinical studies related to interventional intranasal therapies have increased three-folds over the last decade. Specifically, post the onset of the COVID-19 pandemic, extensive research focused on intranasal therapeutics is being carried out due to their proven pharmacological value and favorable safety profiles. Notable examples of intranasal COVID-19 targeting drugs that are currently being evaluated across different phases of development include (in alphabetical order) COVIDROPS™ (Sorrento Therapeutics), DEXANEUROSONE™ (Biomed Industries™) and Zavegepant (Biohaven Pharmaceuticals). 

Despite the several advantages offered by the intranasal route of administration, the delivery of therapies via the aforementioned approach is associated with some challenges, such as mucus and epithelial barriers, low bioavailability of drugs, limited drug absorption and shorter residence time. Most of these concerns can be mitigated via the use of appropriate drug delivery systems. Therefore, several pharmaceutical companies are currently focused on the development of novel drug delivery systems for intranasal therapeutics, since conventional pharmaceutical dosage forms are unable to regulate the rate at which these drugs are delivered to the target site. At present, close to 40 intranasal drug delivery systems are available in the market. Additionally, USD 5.5 billion was invested in this domain, during 2016-2021. In the same time frame, multiple partnership agreements were established between various stakeholders. Driven by the increasing patient population and the growing demand for such therapeutics, this market is anticipated to witness steady growth in the coming years.

Nasal Drug Delivery Market Segmentation Insights

The market research report presents an in-depth analysis of the various companies that are engaged in the development of nasal drug delivery technologies as well and intranasal therapeutics, across different segments, as defined in the table below:

Global Nasal Drug Delivery Market Report Attributes / Market Segmentations

Key Report Attribute Details
Historical Trend 2018-2023
Base Year 2023
Forecast Period 2024-2035
Market Size by 2035 USD 26.8 Billion
CAGR 18.3%
Target Indications
  • Acute Repetitive Clusters
  • Anaphylaxis
  • COVID-19
  • Dry Eye Disease
  • Hypoglycemia
  • Influenza
  • Major Depressive Disorder
  • Migraine
  • Nasal Polyps 
  • Prader-Willi Syndrome
Type of Molecule 
  • Biologics 
  • Small Molecule
Type of Drug
  • TrudhesaTM
  • Tyrvaya
  • VALTACO®
  • SPRAVATO®
  • BAQSIMITM
  • NAYZILAM®
  • Tosyma®
  • XHANCETM
  • SINUVA
  • NeffyTM
  • ZAVEGEPANT (BHV-3500)
  • LV-101
  • MEDI3250
  • DEXANEUROSONE™
Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific
  • Latin America 
  • Middle East and North Africa
Key Companies Profiled
  • Aptar Pharma
  • Nemera
  • Teleflex
  • Mystic Pharmaceuticals 
  • Zeteo Medical

(A full list of operating companies captured is and available in the report)
 

PowerPoint Presentation
(Complimentary)
Available
Customization Scope 15% Free Customization 
Excel Data Packs
(Complimentary)
  • Overall Market Landscape Analysis for Nasal Drug Delivery System
  • Competitiveness Landscape Analysis
  • Clinical Trial Analysis
  • Partnership and Collaboration Analysis
  • Funding and Investment Analysis
  • Value Chain Analysis
  • Patent Analysis
  • Market Forecast and Opportunity Analysis

One of the key objectives of this nasal drug delivery market report was to estimate the current market size, opportunity, and future growth potential for companies active in this market, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period 2024-2035. The market report also features the likely distribution of the current and forecasted opportunity within the nasal drug delivery market across various segments, such as type of target indication (acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps, and prader-willi syndrome), type of molecule (biologics and small molecule), and key geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East, North Africa and rest of the world). 

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Nasal Drug Delivery Market Share Insights

Market Share by Target Indication

The global nasal drug delivery market has a variety of target indications such as Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps, and Prader-Willi Syndrome. As per our market research, in the given target indication, the dry eye disease segment obtains the highest (60%) of the nasal drug delivery market share and is expected to lead the market by 2035. This can be attributed to the widespread prevalence of dry eye syndrome and the advantages of nasal delivery systems in treating dry eye disease. The nasal polyps are likely to propel the market at a CAGR of (28.3%) till 2035.

Market Share by Type of Molecule 

Based on the type of molecules, the nasal drug delivery market is segmented into Biologics and Small Molecules. According to our projection, the small molecules capture the maximum number (95%) of the market share and are projected to continue to dominate the market by 2035. This dominance can be credited to its versatility, enhanced absorption, and established regulatory pathways. Further, the biologics segment is expected to drive the market at a CAGR of (22%) till 2035.

Market Share by Key Drugs

This segment underscores the type of drugs category present in the nasal drug delivery market which include TrudhesaTM, TYRVAYA™, VALTACO®, SPRAVATO®, BAQSIMITM, NAYZILAM®, Tosyma®, XHANCETM, SINUVA, NeffyTM, ZAVEGEPANT (BHV-3500), LV-101, MEDI3250, and DEXANEUROSONE™. As per our projection, TYRVAYA™ leads the drug segment with the largest (60%) share and is likely to retain its dominance till 2035. DEXANEUROSONE™ is estimated to drive the market with a notable CAGR over this projection period owing to the rising incidence of infectious disease, particularly, COVID-19. DEXANEUROSONE™ is one of the leading drugs for COVID-19 infection treatment. Further, it has also been proven to effectively treat neurological disorders or other conditions for which it is indicated.

Market Share by Key Geographical Regions

This segment highlights the distribution of the nasal drug delivery market across various geographies, such as North America, Europe, Asia-Pacific Latin America, Middle East and North Africa. As per our projections, in terms of revenue, North America has been a dominating region with the acquisition of the majority (80%) of the share in the global market for nasal drug delivery. The leading factor behind the region’s dominance is attributed to the robust healthcare infrastructure and advanced research facilities in the region. Along with this, the existence of industry players and their active R&D for novel therapeutics further contribute to its leading position. Moreover, Asia Pacific is a rapidly emerging region in the nasal drug delivery system market and is projected to drive the market at a CAGR of 20% till 2035. The growth of the market in Asia Pacific can be ascribed to the expanding patient population, the growing number of diseases including neurological disorders, and the mounting demand for effective therapeutics.

Nasal Drug Delivery Market: Key Insights

The “Nasal Drug Delivery Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in development of nasal drug delivery technologies and intranasal therapeutics. Key takeaways of the market report are briefly discussed below.

Competitive Landscape of Nasal Drug Delivery Companies

The nasal drug delivery market is fragmented into several small, large, and very large companies. Currently, 19 startup companies are serving in the market and constantly striving and initiating R&D for novel drug delivery systems. Furthermore, to build a competitive edge, leading companies are expanding their portfolio by showcasing the uniqueness of their proprietary intranasal drug delivery system and experimenting with putting drugs or biologics together with devices. 

In addition to this, companies emphasize on collaboration and partnership for developing innovative drug delivery systems.  They are also raising funds and investing in research and development for innovative therapeutics. For instance, an amount of over USD 1200 million has been invested in neurological disorders in the past few years. It is worth highlighting that 49% of small-size companies based in North America are the leading developers in the market.

Market Drivers Analysis: Upsurge in Patient Population to Accelerate the Market Growth

The nasal drug delivery market is expected to witness substantial growth driven by various factors. However, one of the major factors in boosting the market demand is the increasing number of patients with multiple diseases such as Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, and Influenza, coupled with the mounting demand for effective therapeutics. Primarily, the benefits of nasal drug delivery such as its non-invasive route of administration, which is increasingly being preferred by elderly and pediatric patients as compared to oral medication or injections, further contribute to growing demand for such therapeutics. Besides, ongoing technological advancements and growing regulatory support are also likely to drive nasal drug delivery market growth in the future.

Patent Analysis: Nearly 408 Patent Applications Have been Filed to Secure Intellectual Property 

Recently, nearly 408 patent applications have been filed to protect intellectual property. According to the type of patents, the majority (77%) were patent applications and approximately 19% were granted patents. Despite the high number of patents that have been filed, very few belong to the high-value category. According to our analysis, 8.82% of patents have the highest relative valuation.

Trends Analysis in Nasal Drug Delivery Market: Increasing Partnership & Collaboration to Foster Market Prospect

One of the latest trends in the nasal drug delivery market is the growing number of collaborations and partnerships, which have significantly boosted market development through continuous technological advancements. This innovation has spurred the interest of industry players, encouraging the development of novel drug delivery systems. 

Numerous agreements have been signed, with product development and commercialization agreements accounting for the largest share, around 24%. For example, Oyster Point Pharma and Ji Xing Pharmaceuticals have entered into a strategic collaboration to develop and commercialize the nasal sprays OC-01 (Varenicline) and OC-02 (Simplinicline). Additionally, Aptar Pharma has partnered to provide access to its Bidose (BDS) Liquid System device for SLS002, an intranasal ketamine product candidate, under a technological utilization agreement.

Regional Analysis: North America is Anticipated to Lead the Market with Soaring Emergence of Startup Companies

In respect of regional insights, North America plays a critical role in the global market for nasal drug delivery. With the largest market share, North America influences the nasal drug delivery market growth substantially. Various factors contribute to the region’s dominance. Firstly, a rise in the cases of neurological disorders and infectious diseases is raising the market demand. Additionally, the presence of industry players particularly, emerging startup companies has significantly expanded the market potential. For example, some of these start-ups are ARS Pharma, Dauntless Pharmaceuticals, Bryn Pharma, Codagenix, Baudax, and others. It is worth mentioning that including these start-ups, around 84% of the companies are based in North America which propels the market growth in the region.

Key Players in Nasal Drug Delivery Market

Examples of key companies engaged in the nasal drug delivery industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aptar Pharma, Nemera, Teleflex, Mystic Pharmaceuticals, and Zeteo Medical. This market report includes an easily searchable excel database of all the companies developing either intranasal therapeutics or nasal drug delivery technology / systems.

Nasal Drug Delivery Market Report Coverage

  • A detailed overview of the overall market landscape of players engaged in providing intranasal drug delivery systems, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of dosage form (liquid, powder and spray) and type of system (unit dose, multi dose and metered dose).
This image provides list of Intranasal Therapeutic Candidates. Presently, more than 75 intranasal based drug candidates are being investigated, across different phases of development, for the treatment of a myriad of disease indications This image presents current market landscape of	Intranasal Therapeutics. Over 50% of the total intranasal therapeutics in the pipeline are currently in early stages of development and being formulated as small molecule products; such drug candidates are primarily targeting neurological disorders This image provides information and analysis of the start-ups engaged in this domain. At present, 19 start-ups are driving innovation in this domain; various R&D initiatives have been undertaken by these players over the last few years
  • A detailed overview of the overall market landscape of players engaged in providing intranasal therapeutics, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, phase of development (phase I, phase II, Phase II/III, Phase III and Approved), type of molecule (biologics and small molecule) and therapeutic area (cardiovascular disorders, ear disorders, genetic disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, ophthalmic disorders, respiratory disorders and other disorders)
  • An in-depth company competitiveness analysis of intranasal drug delivery system providers based on company strength (in terms of experience and company size), and product portfolio strength (such as number of products, type of dosage form, type of system and volume range).
  • An in-depth analysis of completed, ongoing and planned clinical trials focused on intranasal therapeutics, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and key geographical regions.
  • An analysis of the recent partnerships inked between various players engaged in the development of intranasal therapeutics, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as service agreements, licensing agreements (specific to affiliated technology platforms and product candidates), technology utilization agreements, product manufacturing agreements, product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain.
  • A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by players engaged in this domain, during the period 2016-2021.
This image provides list of Intranasal Drug Delivery Systems. More than 40 intranasal drug delivery systems are currently available in different types of dosage forms, volume ranges and containers This image highlights competitive analysis of players engaged in the domain of Intranasal Drug Delivery Systems. Companies are demonstrating the novelty of their proprietary intranasal drug delivery systems, aiming to further enhance their respective offerings, both in terms of portfolio strength and diversity This image provides information on patents that have been filed / granted related to Intranasal Therapeutics and Drug Delivery Systems. The intellectual property associated with intranasal therapeutics has increased over the years, as numerous patents related to the delivery devices and drug molecules have been filed by / granted to various organizations
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked.
  • An in-depth analysis of patents related to intranasal therapeutics and drug delivery systems, filed / granted, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of applicant, and leading players (in terms of number of patents). In addition, it features a patent valuation analysis, highlighting the qualitative and quantitative aspects of patents.
  • A detailed discussion on the various steps of the supply chain model, namely concept of development & proof of concept, research and development, regulatory approvals and marketing and sales of the intranasal drug delivery systems and the cost requirements across each of the aforementioned stages.
This image highlights the partnership activity undertaken by players engaged in Intranasal Therapeutics and Drug Delivery Systems. A considerable increase in the partnership activity has been witnessed since 2016, indicating a steady rise in the interest of stakeholders in this domain This image provides information on funding and investments made in companies focused on Intranasal Therapeutics and Drug Delivery Systems. Foreseeing lucrative returns, many public and private investors have made investments worth over USD 5 billion, marking a surge in funding activity related to intranasal products This image highlights the market segments of Intranasal Therapeutics and Drug Delivery Systems. The market is expected to witness a healthy growth of over 23% in the coming decade; the opportunity is likely to be well distributed across various target indications, types of molecules and different regions  

Recent Developments in Nasal Drug Delivery Market

In the past few years, the market for nasal drug delivery has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our nasal drug delivery market analysis.

  • In Jan 2024, Recipharm signed into a License & Collaboration Agreement with Medspray and Resyca, aimed at developing nasally-delivered drug products utilizing proprietary soft mist technology.
  • In August 2023, Tiziana Life Sciences announced the FDA clearance of intranasal Foralumab for the treatment of patients suffering from Alzheimer's disease.
  • In June 2023, the FDA announced the extension of its review period of the New Drug Application (NDA) for neffy® (intranasal (IN) epinephrine) for the treatment of severe allergic reactions. 
  • In June 2023, Seelos Therapeutics announced the closure of enrollment of its registration directed study focusing on SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in adults suffering from major depressive disorder.
     

Frequently Asked Questions

Question 1: What are intranasal therapeutics?

Answer: Intranasal therapeutics encompass a wide array of pharmaceuticals which are administered via the intranasal route for better and quick absorption of the drug.

Question 2: How big is the nasal drug delivery market?

Answer: The nasal drug delivery market size is estimated to be worth $ 26.8 billion by 2035.

Question 3: What is the projected market growth of the nasal drug delivery market?

Answer: The nasal drug delivery industry is expected to grow at compounded annual growth rate (CAGR) of 18.3% during the forecast period 2024 - 2035.

Question 4: Who are the leading companies in the nasal drug delivery market?

Answer: Aptar Pharma, Nemera, Teleflex, Mystic Pharmaceuticals and Zeteo Medical.

Question 5: How many intranasal drug candidates are currently being evaluated by companies?

Answer: Over 65 drug candidates are currently being evaluated by players engaged in the nasal drug delivery market.

Question 6: How many nasal drug delivery systems are currently marketed / under development?

Answer: More than 40 intranasal drug delivery systems are currently marketed / under development.

Question 7: Which region is the hub for companies engaged in the nasal drug delivery market?

Answer: North America emerged as the hub for companies, with over 84% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com